Literature DB >> 8014016

Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935-1989.

D L Katz1, T Zheng, T R Holford, J Flannery.   

Abstract

Recent trends in the incidence of renal cancer, stratified by histology, have not been reported. This study utilized data from the Connecticut Tumor Registry (CTR), the oldest population-based cancer registry in the United States, to establish time trends in the incidence of adenocarcinoma and transitional cell carcinoma of the kidney and urinary tract. All 10,209 incident cases of renal cancer reported to the CTR between 1935 and 1989 were analyzed. Regression modelling was employed to determine the effects of age, period, and birth cohort on incidence rates, and to project future trends. The incidence rate of adenocarcinoma increased in females from 0.7/100,000 in 1935-39, to 4.2/100,000 in 1985-89; and in males, from 1.6/100,000 in 1935-39, to 9.6/100,000 in 1985-89. The reported incidence of transitional cell carcinoma increased in males from 0.5/100,000 in 1950-54 to 2.8/100,000 in 1985-89, and in females from 0.2/100,000 to 1.1/100,000 over the same period. Regression modelling revealed that both net and recent drift, the sum of period and cohort slopes, were positive for adenocarcinoma in both sexes, largely due to a positive cohort effect. While the net drift for transitional cell carcinoma was positive, recent drift was negative in both sexes due primarily to a negative cohort effect. Incidence rates of adenocarcinoma are likely to rise in the immediate future, with the rate of rise in females possibly exceeding that in males. Incidence rates of transitional cell carcinoma will stabilize.

Entities:  

Mesh:

Year:  1994        PMID: 8014016     DOI: 10.1002/ijc.2910580111

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Rho GDP dissociation inhibitor-β in renal cell carcinoma.

Authors:  Christoph-Alexander von Klot; Natalia Dubrowinskaja; Inga Peters; Jörg Hennenlotter; Axel S Merseburger; Arnulf Stenzl; Markus A Kuczyk; Jürgen Serth
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

2.  The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages.

Authors:  Tongzhang Zheng; Cairong Zhu; Bryan A Bassig; Simin Liu; Stephen Buka; Xichi Zhang; Ashley Truong; Junhi Oh; John Fulton; Min Dai; Ni Li; Kunchong Shi; Zhengmin Qian; Peter Boyle
Journal:  Int J Epidemiol       Date:  2019-12-01       Impact factor: 7.196

Review 3.  Diagnosis and Treatment of Small Renal Masses: Where Do We Stand?

Authors:  Jerez Izquierdo Tamara; Gómez Rivas Juan; Zondervan Jeannelle Patricia; Vives Dilme Roser; Rodriguez Moisés; Enikeev Dmitry; Serrano Pascual Álvaro; Moreno Sierra Jesús
Journal:  Curr Urol Rep       Date:  2022-05-04       Impact factor: 3.092

4.  Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renal cell carcinoma in older patients.

Authors:  Jae Hee Suh; Tina Oak; Jae Y Ro; Luan D Truong; Alberto G Ayala; Steven S Shen
Journal:  Int J Clin Exp Pathol       Date:  2009-01-30

Review 5.  [Differential diagnosis of renal tumors].

Authors:  P Hallscheidt; A Haferkamp; R Lopez-Benitez; M Palmowski
Journal:  Radiologe       Date:  2008-03       Impact factor: 0.635

6.  Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance.

Authors:  Paul L Crispen; Rosalia Viterbo; Stephen A Boorjian; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

7.  Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol.

Authors:  Jaime A Wong; Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

8.  Contemporary epidemiology of renal cell cancer.

Authors:  Wong-Ho Chow; Susan S Devesa
Journal:  Cancer J       Date:  2008 Sep-Oct       Impact factor: 3.360

9.  Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

Authors:  C A VON Klot; Axel S Merseburger; Markus A Kuczyk
Journal:  Mol Clin Oncol       Date:  2016-04-08

Review 10.  The role of adjuvant immunotherapy in renal cell carcinoma.

Authors:  Peter F A Mulders; Pieter H M De Mulder
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.